This stock is quite new and just upgraded to Nasdaq in September(traded at about 5 at that time). I expect it back to 5 in near term since its CPX-351 will be as first-in line therapy if approved. Also please phase 2b results is good with 2.4 months advantage in OS compared with Standard care, please see below for details: http://www.celatorpharma.com/new/pr_20120605.html Undiscovered stock with huge potential. Good luck.